These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 11705884

  • 1. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H, Nan L, Yu D, Agrawal S, Zhang R.
    Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
    [Abstract] [Full Text] [Related]

  • 2. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H, Yu D, Agrawal S, Zhang R.
    Prostate; 2003 Feb 15; 54(3):194-205. PubMed ID: 12518324
    [Abstract] [Full Text] [Related]

  • 3. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R.
    Mol Med; 2002 Apr 15; 8(4):185-99. PubMed ID: 12149568
    [Abstract] [Full Text] [Related]

  • 4. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R.
    Int J Oncol; 2002 Apr 15; 20(4):745-52. PubMed ID: 11894120
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J, Yang Q, Li J, Zhou S.
    Angiogenesis; 2014 Jan 15; 17(1):37-50. PubMed ID: 23907365
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
    Prasad G, Wang H, Agrawal S, Zhang R.
    Anticancer Res; 2002 Jan 15; 22(1A):107-16. PubMed ID: 12017271
    [Abstract] [Full Text] [Related]

  • 10. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.
    Clin Cancer Res; 2004 Jul 15; 10(14):4858-64. PubMed ID: 15269162
    [Abstract] [Full Text] [Related]

  • 11. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
    Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R.
    Int J Oncol; 2002 Jul 15; 21(1):73-80. PubMed ID: 12063552
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice.
    Wang YJ, Jeng JH, Chen RJ, Tseng H, Chen LC, Liang YC, Lin CH, Chen CH, Chu JS, Ho WL, Ho YS.
    Mol Carcinog; 2002 Aug 15; 34(4):199-210. PubMed ID: 12203371
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
    Zhang R, Wang H, Agrawal S.
    Curr Cancer Drug Targets; 2005 Feb 15; 5(1):43-9. PubMed ID: 15720188
    [Abstract] [Full Text] [Related]

  • 20. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z, Li M, Wang H, Agrawal S, Zhang R.
    Proc Natl Acad Sci U S A; 2003 Sep 30; 100(20):11636-41. PubMed ID: 13130078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.